RecruitingNot ApplicableNCT06087783

PROtein, Leucine and Vitamin D Supplementation In Patients With GYnecologic Cancer Receiving Platinum-based Chemotherapy

PROtein, Leucine and Vitamin D Supplementation In Patients With GYnecologic Cancer Receiving First-line Platinum-based Chemotherapy


Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Enrollment

50 participants

Start Date

Jul 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Open clinical trial addressing the effect of a nutritional support based on whey proteins, leucine and vitamin D on muscle mass and multiple anticancer treatment-related endpoints in patients with gynecologic cancer receiving first-line platinum-based chemotherapy (adjuvant or curative). A comparison to matched historical controls will be performed to address potential evidence of efficacy to be investigated in a subsequent randomized trial.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • histologically confirmed diagnosis of gynecologic cancer (ovarian, uterine, cervical);
  • indication for a first-line chemotherapy (adjuvant or curative) with a platinum-based regimen to be used by investigator's choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines;
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  • signed informed consent.

Exclusion Criteria11

  • age <18 years
  • ECOG performance status >2
  • indication to or ongoing artificial nutrition support
  • known kidney failure (previous glomerular filtration rate <30 ml/min);
  • known liver failure (Child B or C)
  • endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)
  • decompensated diabetes
  • indications related to the study product: more than 10 µg (400 IU) of daily Vitamin D intake from medical sources More than 500 mg of daily calcium intake from medical sources; adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.
  • known allergy to milk, milk products or other components of the proposed interventions
  • inclusion in other nutritional intervention trials
  • patients refusal

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTExperimental product - Fortifit® Powder

Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

OTHERStandard of care

Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement


Locations(1)

IRCCS San Matteo

Pavia, Italy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06087783


Related Trials